Merz Therapeutics

Did you know that 75% to 80% of people living with #cerebralpalsy experience spasticity? This symptom can lead to a limited range of joint motion, reduced motor function, and pain. By addressing these challenges and showing our support, we can help individuals lead more independent and fulfilling lives. Let’s work together to build a more inclusive and supportive community. #BetterOutcomesForMorePatients

As we continue to push the boundaries of innovation in the pharmaceutical industry, the role of patient advocacy organizations in R&D has never been more important. Patient organizations bring invaluable perspectives that help shape clinical development programs, making them more effective and patient-centered. At #MerzTx, we're proud to put patients first: Their voices are not only heard, but they are also integral to our work, from the early stages of research to the final stages of development. Learn more about the patient organizations we work with: https://lnkd.in/dY48tpz7 

Ensuring continued safety of our products is vital to our mission: Better outcomes for more patients. Julia Pfaff, our Head of Pharmacovigilance, sheds light on the critical process of post-approval product monitoring. Explore our clinical breakthroughs: https://lnkd.in/eT_aduCR

Understanding #dystonia can be challenging, as the complex neurological disorder is not widely known. Educating ourselves and others about neurological disorders like dystonia can lead to better support systems and treatment approaches for those affected. Learn more: https://lnkd.in/e-nwzn4m 

In this interview, Dr. Rajiv Reebye discusses the role of collaboration between rehabilitation specialists, neurosurgeons, and orthopedic surgeons in spasticity treatment. Early teamwork, beginning in residency, can set the stage for better outcomes and prepare medical professionals to effectively manage complex cases.

It's hard to believe that it's already been a year since we opened our #MerzTx Nordics affiliate. In that time, we've welcomed talented individuals from Denmark, Norway, and Sweden to our team, and together we've achieved remarkable milestones. We're immensely grateful to each colleague for their unwavering commitment to delivering #BetterOutcomesForMorePatients. Here's to continued success and growth in the journey ahead!

We were delighted to welcome our partner Teijin Limited to our headquarters in Frankfurt, Germany. Throughout our eight-year partnership, we have been able to bring #BetterOutcomesForMorePatients to Japan and address critical unmet needs in spasticity and stroke rehabilitation. Learn more about our partnerships at Merz Therapeutics: https://lnkd.in/ezBCgQNr

For Investors and Medical Media: We are proud to announce that we received approval from Swissmedic for the treatment of lower limb spasticity. This allows us to bring comprehensive treatment solutions to people living with spasticity in Switzerland. A new press release regarding Swissmedic approval is available on our website: https://lnkd.in/eWye7rsT

To all neurologists: We are pleased to share an insightful new scoping review on how definitions of treatment duration in cervical #dystonia phase 3 trials relate to the patient's quality of life. Read the full article here: https://lnkd.in/eQ5XNUNM

At Merz Therapeutics, we're dedicated to reimagining possibilities and setting ambitious goals. As we evolve, we're not only shaping the future of our company, but also the future of healthcare. Find out how we can drive scientific progress together: https://lnkd.in/egchjjFy